Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views

NewEdge Wealth LLC increased its Novartis AG position by 3.9% in Q4 2025 to $69.67 million, while analysts maintain a Hold rating with a $141.20 target. The stock holds strong market cap status.

NewEdge Wealth LLC raised its stake in Novartis AG by 3.9% during the fourth quarter of 2025, lifting holdings to 505,339 shares valued at $69.67 million as of the period's end, MarketBeat as of 05/10/2026. This move comes as Novartis reported a quarterly revenue dip of 0.9% year-over-year, alongside a net margin of 24.87% and return on equity of 38.82%. Analyst consensus remains at Hold with a $141.20 price target, following earnings that missed EPS estimates but beat on revenue.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis AG
• Sector/industry: Pharmaceuticals
• Headquarters/country: Basel, Switzerland
• Core markets: US, Europe, Asia
• Key revenue drivers: Innovative medicines in cardio, oncology
• Home exchange/listing venue: NYSE (NVS)
• Trading currency: USD

Novartis AG: core business model

Novartis AG, a Swiss multinational pharmaceutical company headquartered in Basel, focuses on researching, developing, manufacturing, and commercializing prescription medicines and health-care products, MarketBeat as of 05/10/2026. The company operates in core therapy areas including cardiovascular, oncology, immunology, neuroscience, and more, with a portfolio of blockbuster drugs driving revenue.

Novartis emphasizes innovation through R&D investments, maintaining a pipeline of novel therapies. It has streamlined operations by divesting non-core assets, such as its 71% stake in Novartis India in February 2026, to focus on high-growth innovative medicines.

Main revenue and product drivers for Novartis AG

Key products like Entresto (sacubitril/valsartan) for heart failure remain central, bolstered by patent protections amid ongoing litigation such as Novartis AG v. Alembic in Delaware, which extended exclusivity against generics, per legal updates. Other drivers include oncology drugs and immunology treatments contributing to global sales.

The company's presence in India supports global commercialization, with contributions to nearly every molecule, including early Phase I studies, enhancing its innovation pipeline as stated by Novartis India MD Amitabh Dube.

Industry trends and competitive position

Novartis holds a strong position in the global pharma sector, ranking among the top companies by market cap at £204.40 billion as of May 2026, making it the 52nd most valuable worldwide, CompaniesMarketCap as of 05/2026. On March 11, 2026, its market cap stood at £222-224.91 billion across sources like Nasdaq.

In a competitive landscape, Novartis differentiates through its focused portfolio post-spin-offs, targeting US investors via NYSE listing (NVS) with significant exposure to the US healthcare market, a key revenue driver.

Why Novartis AG matters for US investors

Listed on the NYSE as NVS, Novartis AG offers US investors access to a leading European pharma giant with substantial US market revenue from drugs like Entresto. Its ADR structure facilitates trading in USD, aligning with US portfolios amid global health trends.

Conclusion

Novartis AG continues to navigate pharma challenges with solid fundamentals, evidenced by institutional buying from NewEdge Wealth and a robust market cap. While recent earnings showed revenue softness, strong margins and patent wins like Entresto support its position. US investors track its NYSE performance for global exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.